Shopping Cart
Remove All
Your shopping cart is currently empty
Vorsetuzumab (Synonyms: SGN-70)
Catalog No. T77362 Copy Product Info
🥰Excellent
Vorsetuzumab (Anti-Human CD70 Recombinant Antibody) is a monoclonal antibody that targets the CD70 antigen. It exhibits anticancer activity by enhancing macrophage-associated phagocytosis of kidney cancer cells and inhibiting Burkitt lymphoma.
Vorsetuzumab
Copy Product Info🥰Excellent
Catalog No. T77362
Synonyms SGN-70
Vorsetuzumab (Anti-Human CD70 Recombinant Antibody) is a monoclonal antibody that targets the CD70 antigen. It exhibits anticancer activity by enhancing macrophage-associated phagocytosis of kidney cancer cells and inhibiting Burkitt lymphoma.
Vorsetuzumab
Cas No. 1165740-62-4
Customer service consultation
| Pack Size | Price | USA Stock | Global Stock | Quantity |
|---|---|---|---|---|
| 1 mg | $197 | - | In Stock | |
| 5 mg | $596 | - | In Stock | |
| 10 mg | $959 | - | In Stock | |
| 25 mg | $1,420 | - | In Stock | |
| 50 mg | $1,920 | - | In Stock | |
| 100 mg | $2,590 | - | In Stock |
For In stock only · Estimated delivery: USA Stock (1-2 days) Global Stock (5-7 days)
Add to Cart
Add to Quotation
For research use only—not for human use. No sales to individuals. Use as intended only.
Batch Information
Select Batch
Purity:99.29% (SEC-HPLC)
Appearance:Liquid
Color:Transparent
Contact us for more batch information
Resource Download
Product Introduction
Bioactivity
Related Conjugates and Formulations
Antigen Details
Chemical Properties
Antibody Information
Storage & Solubility Information
| Description | Vorsetuzumab (Anti-Human CD70 Recombinant Antibody) is a monoclonal antibody that targets the CD70 antigen. It exhibits anticancer activity by enhancing macrophage-associated phagocytosis of kidney cancer cells and inhibiting Burkitt lymphoma. |
| In vitro | In vitro, vorsetuzumab (10 μg/mL; 2 h) augments macrophage-dependent phagocytosis of renal carcinoma cells[1]. Vorsetuzumab (10 μg/mL; 2 h) can be developed into a bispecific anti-human CD70/KWAR23 antibody. The results show that KWAR23 moderately induced macrophage phagocytosis of four renal carcinoma cell lines (RCC4, RCC10, TK10, and Caki-1)[1]. |
| In vivo | In SRG mice, vorsetuzumab (10 mg/kg; i.p.; every other day; for 12 d) inhibits the growth of Burkitt’s lymphoma cells[1]. |
| Synonyms | SGN-70 |
| Reactivity | Human |
| Application | Functional assay |
| Antibody Type | Monoclonal |
| Formulation | Supplied as a sterile solution in a buffered formulation system (e.g., phosphate-, citrate-, or amino acid-based). Please refer to the CoA for lot-specific composition. |
| Endotoxin | <1.0 EU/mg |
| Conjucates | Unconjugated |
| Gene ID | |
| Uniprot ID | |
| Target | TNFSF7/CD27L/CD70 |
| Molecular Weight | 146.1 kDa |
| Cas No. | 1165740-62-4 |
| Isotype | Human IgG1 kappa |
| Recommended Isotype Control |
| Storage | store at low temperature | -20°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
Calculator
Keywords
Preview
Related Tags: buy Vorsetuzumab | purchase Vorsetuzumab | Vorsetuzumab cost | order Vorsetuzumab | Vorsetuzumab in vivo | Vorsetuzumab in vitro | Vorsetuzumab molecular weight
Generate Quote
Catalog No.: Cas No.:
Add
| Size | Quantity | Unit Price | Amount | Operation |
|---|
Generate Quote
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.